Paper Details

  1. Home
  2. Paper Details

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Author: BajelAshish, BrachmannCarrie Baker, CourbyStephane, GriesshammerMartin, HuangDaniel, KawashimaJun, MaltzmanJulia D, MesaRuben A, ShaoLixin, VerstovsekSrdan, XinYan

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2 study evaluated the efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The study was terminated due to limited efficacy, with only two out of 39 patients achieving the primary endpoint. While momelotinib demonstrated stable plasma levels, it was associated with frequent adverse events, including headache, dizziness, and fatigue.
Paper Details　
Original Abstract of the Article :
Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100mg and 200mg) for the treatment of polycythemia vera (PV...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28622623

データ提供：米国国立医学図書館（NLM）

Momelotinib: A New Hope in the Desert of Myeloproliferative Neoplasms

Myeloproliferative neoplasms, a group of blood cancers characterized by uncontrolled proliferation of blood cells, present a significant challenge for healthcare providers. This study explores the efficacy and safety of momelotinib, a potent inhibitor of JAK1 and JAK2, as a potential treatment for polycythemia vera (PV) and essential thrombocythemia (ET), two types of myeloproliferative neoplasms. The researchers conducted a phase 2 clinical trial to evaluate the effectiveness of momelotinib in reducing disease symptoms and improving patient outcomes. Their findings, though limited in scope, offer valuable insights into the potential benefits and risks of this novel therapeutic agent.

A Glimpse into the Therapeutic Potential of Momelotinib

The study, like a desert oasis offering a temporary respite from the harsh environment, provides a glimpse into the potential of momelotinib as a treatment for PV and ET. While the study was terminated early due to limited efficacy, the researchers observed positive responses in a small number of patients. This finding, though preliminary, warrants further investigation to explore the potential of momelotinib as a therapeutic option for these diseases.

Navigating the Terrain of Drug Development

This research, like a careful exploration of a new desert landscape, highlights the complex challenges of drug development. While the study did not achieve its primary endpoint, it provided valuable insights into the safety profile of momelotinib and identified potential side effects that require further investigation. This information is essential for guiding future research and development of this promising therapeutic agent.

Dr. Camel's Conclusion

This study, like a desert traveler encountering a rocky outcrop, reveals the challenges and opportunities inherent in the quest for new treatments for myeloproliferative neoplasms. While the study did not meet its primary endpoint, it provided valuable insights into the potential benefits and risks of momelotinib, guiding future research towards a more effective and safe treatment for these debilitating diseases.

Date :
  1. Date Completed 2017-10-31
  2. Date Revised 2021-06-04
Further Info :

Pubmed ID

28622623

DOI: Digital Object Identifier

NIHMS1698100

Related Literature

Article Analysis
・Effects of momelotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.